Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer.

Horimoto, Yoshiya; Arakawa, Atsushi; Tanabe, Masahiko; Sonoue, Hiroshi; Igari, Fumie; Senuma, Koji; Tokuda, Emi; Shimizu, Hideo; Kosaka, Taijiro; Saito, Mitsue

Horimoto, Yoshiya; Arakawa, Atsushi; Tanabe, Masahiko; Sonoue, Hiroshi; Igari, Fumie; Senuma, Koji; Tokuda, Emi; Shimizu, Hideo; Kosaka, Taijiro; Saito, Mitsue.

Affiliation

Horimoto Y; Department of Breast Oncology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, 113-0033 Tokyo, Japan. yoshiyahorimoto@hotmail.com.

BMC Cancer ; 14: 550, 2014 Jul 30.

Article in En | MEDLINE | ID: mdl-25073969

Subject(s)

Antineoplastic Agents/administration & dosage; Breast Neoplasms/diagnosis; Ki-67 Antigen/metabolism; Receptor, ErbB-2/metabolism; Antineoplastic Agents/therapeutic use; Breast Neoplasms/drug therapy; Breast Neoplasms/pathology; Female; Humans; Middle Aged; Neoadjuvant Therapy; Survival Analysis; Treatment Outcome

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Receptor, ErbB-2 / Ki-67 Antigen / Antineoplastic Agents Type of study: Prognostic_studies Limits: Female / Humans / Middle aged Language: En Journal: BMC Cancer Journal subject: NEOPLASIAS Year: 2014 Document type: Article Affiliation country: Japan

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google